Day 1
Day 1
- Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
Workshop Description:
This workshop will address different strategies for overcoming manufacturing challenges of synthetic RNA therapeutics. It will also discuss methods for defining CMC control strategies along the development pathway from early clinical development through later stages of development. A variety of different examples and case studies will be presented to give attendees a good understanding of the current bottlenecks, potential solutions and future directions in oligonucleotide CMC and manufacturing.
Who should attend?
Anyone interested in development of oligonucleotide therapeutics; Anyone interested in outsourcing the manufacturing of oligonucleotide therapeutics to a CMO / CRO. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management.
- Thomas Rupp - Owner & Principal, Thomas Rupp Consulting, Germany
Workshop Description:
Peptides fall between small molecules and biologics in terms of molecular weight and size. Additionally, the complexity of peptide therapeutics is increasing with unnatural amino acid substitutions and various covalent modifications (lipidation, PEGylation). This results in analytical challenges! Learn from the experts on strategies and best practices. Hear case studies from companies working in this area.
Who should attend?
Anyone interested in the analysis and bioanalysis of peptide therapeutics. This includes Research scientists, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management
- Bruce Morimoto, PhD - Vice President, Drug Development, Alto Neuroscience
- Alaric Desmarchelier, PhD - Business Development Manager - Peptides, Almac Group
- Michael McGinley - Director, Global Applications, Phenomenex
- Juerg Tschopp, PhD - Principal Scientist, Stratum Medical Corporation
- Bruce Morimoto, PhD - Vice President, Drug Development, Alto Neuroscience
- Jennifer Lockridge, PhD - VP, Dicerna TRU Early Development, Novo Nordisk
- Shalini Andersson, PhD - Vice President of Oligonucleotide Discovery, AstraZeneca
- Sudhir Agrawal - President and Founder, Arnay Sciences
- Yuji Nishiuchi, Ph.D. - Director of Research and Development, GlyTech, Inc.
- Ryuji Hayashi, PhD - Group Head, Discovery Chemistry Department, Research Division, Chugai Pharmaceutical Co., Ltd.
- Yutaka Okada - President and Representative Director, Alnylam Japan KK
- Leo Qian, PhD - Co-Founder and Vice President, Discovery Research, Entrada Therapeutics
- Brett Monia, PhD - Chief Executive Officer, Ionis Pharmaceuticals